Ausgabe 1/2007
Inhalt (13 Artikel)
Are we victims of our own success in cardiovascular therapeutics?
Afshin Farzaneh-Far, Peter Libby
Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important?
Tracie C. Collins, Peter H. Jones
Statin therapy in cardiovascular diseases other than atherosclerosis
Dominique Beaudry, Kenneth E. Stone, Suzanne Wetherold, John Hemphill, Dat Do, John McClish, Robert Chilton
Will torcetrapib be the next big thing in coronary heart disease risk reduction?
James M. McKenney, John A. Hoekstra
Modifying the anti-inflammatory effects of high-density lipoprotein
Benjamin J. Ansell, Gregg C. Fonarow, Mohamad Navab, Alan M. Fogelman